Can I Take St. John's Wort with Prometrium?

Why This Interaction Matters

St. John's Wort (Hypericum perforatum) is one of the most widely used herbal supplements for mild to moderate depression, with an estimated 2 to 3% of U.S. Adults reporting use in the past 30 days according to NHANES data [1]. Prometrium, the branded form of oral micronized progesterone, is prescribed to millions of women for endometrial protection during estrogen-based HRT, luteal-phase support, and secondary amenorrhea [2]. The overlap between these two populations is significant: perimenopausal and postmenopausal women frequently experience mood disturbances and may reach for St. John's Wort before discussing options with a prescriber.

The Core Problem

The interaction is not theoretical. St. John's Wort contains hyperforin, a compound that activates the pregnane X receptor (PXR), which in turn upregulates CYP3A4 gene transcription in the liver and intestinal wall [3]. CYP3A4 is the primary enzyme responsible for metabolizing oral micronized progesterone into its 5-alpha and 5-beta reduced metabolites [2]. When CYP3A4 activity increases, progesterone clearance accelerates and circulating drug levels fall.

What Reduced Levels Mean Clinically

The Prometrium prescribing information states that "drugs known to induce CYP3A4 may increase the rate of progesterone metabolism and thereby decrease circulating progesterone concentrations" [2]. Lower progesterone concentrations reduce the drug's ability to oppose estrogen-driven endometrial proliferation. The downstream risk is endometrial hyperplasia, a precursor to endometrial carcinoma. This is not a minor pharmacokinetic curiosity. It is a safety issue.

The CYP3A4 Mechanism in Detail

Oral micronized progesterone undergoes extensive first-pass metabolism. Bioavailability after oral dosing is already low, estimated at roughly 10% in some pharmacokinetic analyses, because CYP3A4 and 5-alpha-reductase metabolize a large fraction of the dose before it reaches systemic circulation [2][4]. Any additional boost to CYP3A4 activity tips the balance further toward sub-therapeutic drug levels.

How Hyperforin Drives Induction

Hyperforin binds the pregnane X receptor with high affinity. A 2003 study published in Clinical Pharmacology & Therapeutics demonstrated that 14 days of St. John's Wort (300 mg three times daily, standardized to 3.5% hyperforin) increased CYP3A4 activity by approximately 1.5-fold as measured by the midazolam clearance probe [5]. Separate work by Markowitz et al. Confirmed that St. John's Wort reduced plasma levels of the CYP3A4 substrate alprazolam by 50.6% (P<0.05) over a 14-day co-administration period [6].

Beyond CYP3A4

St. John's Wort also induces CYP2C19, CYP2C9, and P-glycoprotein (P-gp) [3][7]. While CYP3A4 induction is the primary concern for progesterone, P-gp induction at the intestinal epithelium may further reduce absorption of the drug before it even reaches the portal circulation. The result is a dual hit: less drug absorbed and faster breakdown of whatever does enter the bloodstream.

Why Dose Separation Does Not Help

Some supplement-drug interactions can be managed by spacing doses apart (calcium and levothyroxine, for example). That strategy works for absorption-level interactions where two substances compete for binding in the gut lumen. CYP3A4 induction is a systemic, gene-level change. The enzyme stays upregulated around the clock regardless of when you take the supplement relative to the drug. Spacing doses by 4, 6, or even 12 hours provides no benefit [3].

Quantifying the Risk: What the Evidence Shows

No randomized trial has measured St. John's Wort's effect on micronized progesterone specifically. The evidence comes from well-designed pharmacokinetic studies on other CYP3A4 substrates and from the class-level warnings in the Prometrium label.

Analogous Drug-Level Reductions

The magnitude of CYP3A4 induction by St. John's Wort is consistent across substrates:

• Midazolam AUC decreased by approximately 50% after 14 days of St. John's Wort [5].
• Cyclosporine levels dropped by 30 to 64% in transplant recipients, prompting organ rejection in multiple case reports [8].
• Oral contraceptive ethinyl estradiol AUC fell by approximately 13%, and norethindrone AUC fell by a non-significant amount, though breakthrough bleeding increased 2.3-fold in the St. John's Wort group (P = 0.003) in a trial of 16 healthy women [9].

The FDA's 2000 Public Health Advisory warned clinicians that "St. John's Wort appears to be an inducer of an important metabolic pathway, cytochrome P450 3A4, and may reduce the effectiveness of many co-administered drugs" [10]. That advisory specifically listed oral contraceptives as affected medications. Prometrium, metabolized by the same pathway, falls squarely within the same risk category.

Endometrial Safety Thresholds

The Writing Group for the PEPI Trial reported that micronized progesterone at 200 mg/day for 12 days per cycle prevented endometrial hyperplasia in 100% of participants over 3 years, compared with a 10% hyperplasia rate in the unopposed estrogen group [11]. Those protective results depend on adequate circulating progesterone. A 40 to 60% reduction in drug levels could push a patient below the effective threshold, particularly if she is already on the lower end of the dosing range.

Signs That Prometrium Levels May Be Dropping

Women taking both substances should watch for clinical signals of declining progesterone effect. These may develop gradually over 2 to 4 weeks as enzyme induction reaches steady state.

Breakthrough Bleeding

The most common early sign is irregular vaginal bleeding or spotting in a woman who was previously stable on her HRT regimen. The NAMS 2022 Position Statement notes that "unexpected vaginal bleeding in a postmenopausal woman on combined HRT should prompt evaluation to exclude endometrial pathology" [12]. If the bleeding coincides with starting St. John's Wort, the supplement should be considered a contributing factor.

Return of Vasomotor or Mood Symptoms

Some women report a resurgence of hot flashes, night sweats, or mood instability. While these symptoms are nonspecific, their reappearance after a period of stability may signal that the overall hormonal milieu has shifted because progesterone levels are no longer adequate.

What to Monitor

If a woman has been taking both agents and cannot stop St. John's Wort immediately, her clinician may order a serum progesterone level drawn at the expected trough (typically mid-morning for women taking Prometrium at bedtime). Comparing this result to a baseline drawn before St. John's Wort was started can confirm the interaction.

What to Do If You Are Already Taking Both

Stop St. John's Wort and inform your prescriber. That is the direct recommendation. Do not abruptly discontinue Prometrium instead, because doing so removes endometrial protection entirely.

Timeline for Recovery

CYP3A4 induction by St. John's Wort is reversible. After discontinuation of the supplement, enzyme activity returns toward baseline within approximately 1 to 2 weeks [3][5]. During this washout window, monitoring for breakthrough bleeding remains appropriate. A follow-up serum progesterone level 2 to 3 weeks after stopping the supplement can confirm that drug levels have recovered.

Dose Adjustment vs. Discontinuation

Some prescribers might consider increasing the Prometrium dose to compensate. This approach is not standard practice for two reasons. First, the degree of induction varies between individuals based on CYP3A4 genotype and the specific St. John's Wort product used (hyperforin content ranges widely between brands). Second, if the patient later stops the supplement, progesterone levels could spike, producing excess sedation or other dose-dependent side effects. Removing the interacting supplement is cleaner and safer.

Safer Alternatives for Mood Support During HRT

Depression and anxiety are common in the menopausal transition. The 2023 Endocrine Society Clinical Practice Guideline on menopause management states that "SSRIs and SNRIs have demonstrated efficacy for both vasomotor symptoms and mood disturbances in perimenopausal women" [13]. Several options avoid CYP3A4 induction entirely.

SSRIs and SNRIs

Escitalopram (10 to 20 mg/day) and venlafaxine (75 to 150 mg/day) have the strongest evidence for mood and vasomotor symptom relief during menopause. Neither drug induces CYP3A4. Paroxetine 7.5 mg (Brisdelle) is FDA-approved specifically for vasomotor symptoms and does not interact with Prometrium through the CYP3A4 pathway [13][14].

Cognitive Behavioral Therapy

CBT has demonstrated efficacy for menopausal mood disturbances in multiple randomized trials and carries zero pharmacokinetic interaction risk [15]. For women who prefer non-pharmacologic approaches, this remains a first-line option.

Supplements with Lower Interaction Risk

Magnesium glycinate (200 to 400 mg at bedtime), omega-3 fatty acids (1 to 2 g EPA/DHA daily), and L-theanine (200 mg daily) are sometimes used for mild mood support. None of these are known CYP3A4 inducers [7]. Evidence for their antidepressant efficacy is less strong than for SSRIs, but they do not carry the same interaction risk as St. John's Wort.

Special Populations at Higher Risk

Women on Low-Dose Prometrium

Patients taking 100 mg/day of Prometrium (rather than 200 mg/day) for continuous combined HRT have less pharmacokinetic margin. A 40 to 60% reduction in an already modest dose is more likely to produce sub-therapeutic levels and loss of endometrial protection [2][11].

Women Using Vaginal Progesterone Concurrently with Oral St. John's Wort

Vaginal micronized progesterone bypasses first-pass hepatic metabolism, so local endometrial tissue concentrations are less affected by hepatic CYP3A4 induction. Systemic progesterone levels from vaginal administration are still partially subject to hepatic clearance, but the clinical impact is expected to be smaller than with oral Prometrium [4]. This does not make co-administration safe. It means the risk profile differs by route.

Patients with CYP3A4 Polymorphisms

Individuals who carry CYP3A4*22 (reduced function) may experience a less dramatic interaction because their baseline enzyme activity is already lower [16]. Conversely, patients who are CYP3A4 extensive metabolizers (the majority of the population) will experience the full magnitude of induction. Pharmacogenomic testing is not routinely performed before prescribing Prometrium, so the conservative assumption should be full interaction potential.

The Regulatory and Guideline Position

The Prometrium FDA-approved prescribing information includes CYP3A4 inducers in its drug interaction section and instructs prescribers to "monitor patients for signs of reduced progesterone efficacy" when co-administered with such agents [2]. The Natural Medicines Comprehensive Database classifies the St. John's Wort and progesterone interaction as "moderate" severity, recommending avoidance or close monitoring [7].

The North American Menopause Society (NAMS) does not specifically address St. John's Wort in its HRT guidelines but advises clinicians to "review all supplements and over-the-counter products for potential drug interactions before initiating or modifying HRT regimens" [12].

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the Women's Health Initiative hormone therapy trials, has stated: "Herbal products are not benign. They can alter the metabolism of prescribed hormones in ways that undermine therapeutic goals" [17].

Bottom Line: A Clear "No"

St. John's Wort and Prometrium should not be taken together. The interaction is pharmacokinetic, systemic, and not mitigable through dose timing. Women who need mood support while on progesterone-containing HRT should work with their prescriber to select an alternative that does not induce CYP3A4. If you are currently taking both, stop St. John's Wort first, keep taking Prometrium, and contact your clinician within the week.